Modalis Therapeutics Announces LAMA2 Gene Therapy Study

While we are thrilled to share a recent press release from Modalis Therapuetics, it’s important to keep in mind that the information provided includes “forward‑looking statements.” That means the company is sharing what they hope or plan to do, but these steps are not guaranteed and can change.

The scientific paper mentioned in the press release describes years of careful testing of Modalis’ experimental therapy for LAMA2 (called MDL‑101) in animal models. Publishing this work is an important milestone. It shows that the company has gathered solid early data and is now sharing it openly with the scientific and medical community, which is a good sign of seriousness and transparency.

Cure CMD continues to support Modalis as they begin connecting with experts and potential clinical sites for the first human safety study (a phase 1/2 clinical trial).

It’s important to be cautious. There is still no set timeline for when the clinical trial protocol will be finalized, which institutions will participate, or when the necessary regulatory approvals will be in place. These steps take time.

This release and related publication offer room for careful optimism as the program continues to move through the necessary steps.